Compare ASE Technology Holding Co Ltd (ASX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASE Technology Holding Co Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? ASE Technology Holding Co Ltd trades at $41.01 (market cap $87.94B), while State Street SPDR S&P Biotech ETF trades at $154.27. The key difference: ASE Technology Holding Co Ltd pays a 1.03% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| ASX | XBI | |
|---|---|---|
Market Cap | $87.94B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $45.12 | $164.28 |
52-Week Low | $9.50 | $85.16 |
Enterprise Value | $92.38B | — |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASE Technology Holding (ASX) trades at $40.56, down 4.92% over 24 hours, with a neutral technical signal. The company shows strong earnings momentum with three consecutive quarterly beats and robust cash flow growth. Revenue reached $645.39B in 2025 with net income of $40.02B, while analyst sentiment remains positive with 80% buy ratings. Recent news highlights AI-driven packaging demand and LEAP business growth exceeding $3.5B in 2026 revenue outlook.
The stock presents growth potential from AI infrastructure demand and margin expansion, though elevated P/E ratio of 63.65 suggests premium valuation. Key risks include semiconductor cycle volatility and execution challenges in scaling advanced packaging capacity. Institutional ownership trends and positive earnings revisions support the bullish case, but investors should monitor competitive pressures in the semiconductor packaging sector.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
